# A Study to Investigate Lung Deposition of Radiolabelled OligoG

> **NCT01991028** · PHASE2 · COMPLETED · sponsor: **BDD Pharma Ltd** · enrollment: 10 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Radiolabelled OligoG CF-5/20 DPI
- **DRUG:** Radiolabelled OligoG CF-5/20 6% Solution

## Key facts

- **NCT ID:** NCT01991028
- **Lead sponsor:** BDD Pharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2015-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01991028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01991028, "A Study to Investigate Lung Deposition of Radiolabelled OligoG". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01991028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*